title: Primary carcinoma of the vagina: Tata Memorial Hospital experience.
abstract: OBJECTIVE
  Carcinoma of the vagina is a rare gynecological malignancy comprising approximately 2% of all the gynecological malignancies. We have analyzed the treatment outcome of the patients treated at the Tata Memorial Hospital from January 1984 to December 1993.
  
  
  METHODS
  In this 10-year period, 134 patients of primary vaginal cancers were registered at our hospital. Of these, 75 patients received complete treatment and are analyzed.
  
  
  RESULTS
  Disease-free survival (DFS) for the whole group is 50%, and overall survival (OAS) is 60%. Most locoregional recurrences and distant failures are noted in the 2 years following treatment. DFS at 5 years is as follows: Stage I (5 patients), Stage IIA (37 patients), Stage IIB (15 patients), Stage III (14 patients), and Stage IV (4 patients); are 40%, 55%, 60%, 50%, and 25%, respectively. The DFS for patients with complete response (42 patients) to external radiation at 5 years is 68%, with partial response (25 patients) is 35%, and with poor or no response (6 patients) is 18% (p = 0.0000). We observed that brachytherapy was an important part of the treatment, and patients who received brachytherapy (59 patients), either with a vaginal intracavitary applicator (30 patients) or interstitial implant (29 patients) had a DFS of 53% and 56%, respectively, while 15 patients who received external radiation alone had a DFS of 30%. Patients receiving brachytherapy within 4 weeks of external radiation had a DFS of 60% as compared to 30% when the interval was more than 4 weeks.
  
  
  CONCLUSIONS
  The factors indicating prognosis are: site and extent of involvement, presence of lymph nodes at presentation, technique of brachytherapy, and interval between external radiation and brachytherapy.
authors.affiliation: Department of Radiation Oncology, Tata Memorial Hospital, Parel, India.
authors.forename: S
authors.initials: S
authors.lastname: Pingley
authors.forename: S K
authors.initials: SK
authors.lastname: Shrivastava
authors.forename: R
authors.initials: R
authors.lastname: Sarin
authors.forename: J P
authors.initials: JP
authors.lastname: Agarwal
authors.forename: S
authors.initials: S
authors.lastname: Laskar
authors.forename: D D
authors.initials: DD
authors.lastname: Deshpande
authors.forename: K A
authors.initials: KA
authors.lastname: Dinshaw
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D014625:Vaginal Neoplasms / Q000473:pathology* / Q000532:radiotherapy* / Q000601:surgery